Physician profile
David S Klein
NPI 1215943360
$3,818.18
in general payments reported to CMS, 2019-2025
28 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $551 · 2021: $643 · 2022: $903 · 2023: $464 · 2024: $353 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.43 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.16 | 2021-2025 | |
| Amgen INC. | $431.20 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $274.43 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $266.10 | 2022-2023 | Nexletol, Contrave, Nexlizet |
| Pfizer INC. | $211.79 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $203.99 | 2020-2022 | |
| Indivior INC. | $196.45 | 2020-2021 | |
| Lilly USA, LLC | $174.11 | 2019-2025 | Emgality, Zepbound |
| Protega Pharmaceutials INC | $158.63 | 2024-2025 | Roxybond |
| Centinel Spine, LLC | $154.71 | 2022 | |
| Idorsia Pharmaceuticals US INC | $152.35 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.26 | 2019 | |
| Scilex Pharmaceuticals INC. | $149.12 | 2020-2022 | |
| Horizon Therapeutics Plc | $130.23 | 2021-2022 | |
| Mdd US Operations, LLC | $105.77 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $89.61 | 2019-2021 | |
| Csl Behring | $73.92 | 2023 | Hizentra |
| Uswm, LLC | $71.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.68 | 2019-2020 | |
| Exact Sciences Corporation | $45.81 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $43.51 | 2022 | |
| Zyla Life Sciences, INC. | $28.27 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $23.30 | 2022 | |
| Alkermes, INC. | $20.96 | 2019 | |
| Kaleo, INC. | $19.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.46 | 2023 | Adthyza |
| Hikma Pharmaceuticals USA | $17.65 | 2022 | |
| Orexo US, INC. | $16.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.